Inogen (NASDAQ:INGN) EVP Boyer Jennifer Yi Sells 10,770 Shares

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,770 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $6.53, for a total value of $70,328.10. Following the completion of the transaction, the executive vice president directly owned 15,977 shares of the company’s stock, valued at approximately $104,329.81. This represents a 40.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Inogen Trading Up 0.8%

Shares of INGN stock traded up $0.05 during trading on Tuesday, hitting $6.14. The company’s stock had a trading volume of 609,667 shares, compared to its average volume of 359,619. The company has a market cap of $166.22 million, a PE ratio of -6.67 and a beta of 1.60. The business has a fifty day moving average of $6.60 and a 200-day moving average of $6.49. Inogen, Inc has a 52 week low of $5.34 and a 52 week high of $9.13.

Inogen (NASDAQ:INGN) last released its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The business had revenue of $85.11 million during the quarter, compared to the consensus estimate of $82.35 million. As a group, research analysts predict that Inogen, Inc will post -0.77 EPS for the current year.

Institutional Investors Weigh In On Inogen

Several institutional investors have recently made changes to their positions in INGN. Quarry LP purchased a new stake in shares of Inogen during the fourth quarter worth $27,000. Torren Management LLC purchased a new stake in shares of Inogen in the fourth quarter worth $51,000. Prelude Capital Management LLC purchased a new stake in shares of Inogen in the third quarter worth $82,000. Corient Private Wealth LLC purchased a new stake in shares of Inogen in the fourth quarter worth $84,000. Finally, MetLife Investment Management LLC raised its position in shares of Inogen by 72.2% in the fourth quarter. MetLife Investment Management LLC now owns 12,699 shares of the medical technology company’s stock worth $85,000 after buying an additional 5,325 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on INGN. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Friday, May 8th. Freedom Capital raised Inogen to a “strong-buy” rating in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inogen presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.